This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Kinetic Concepts, Inc. (NYSE: KCI), announced today that Michael G. Franz, M.D., FACS, has been named vice president of Global Clinical & Medical Affairs for LifeCell™, a business unit of KCI that specializes in regenerative medicine.
As VP of Global Clinical & Medical Affairs for LifeCell™, Franz will be responsible for establishing overall clinical and medical strategies, completing clinical studies and providing input into new product activities. He will also work closely with the commercial and research & development teams company-wide.
Franz most recently served as chief, Division of Minimally Invasive Surgery, University of Michigan Department of Surgery, Section of General Surgery. He has more than 20 years of surgical medical experience and is a globally recognized leader and published researcher in the field of wound healing, abdominal wall pathophysiology, tissue engineering and surgical innovation. He previously served on KCI’s Scientific Advisory Board, a committee of leading clinical experts that provides medical guidance to the company.
“Mike shares KCI’s deep passion for regenerative medicine, the advancement of surgical techniques and maximizing patient outcomes,” said Lisa Colleran, president, LifeCell™. “As we continue to grow and launch more products in more places, his expertise in clinical evidence and patient efficacy, and his research in wound healing and tissue engineering around the world, will greatly contribute to our continued success and innovation.”
"Mike is an internationally recognized expert and authority in the field of biologics and biologic materials," said Ron Silverman, M.D., chief medical officer, KCI. "His scientific and critical thinking will further KCI's commitment to improving the lives of patients."
Kinetic Concepts, Inc. (NYSE:KCI) is a leading global medical technology company devoted to the discovery, development, manufacture and marketing of innovative, high-technology therapies and products for the wound care, tissue regeneration and therapeutic support system markets. Headquartered in San Antonio, Texas, KCI's success spans more than three decades and can be traced to a history deeply rooted in innovation and a passion for significantly improving the healing and the lives of patients around the world. The company employs approximately 7,100 people and markets its products in more than 20 countries. For more information about KCI and how its products are changing the practice of medicine, visit